The European Union’s drug regulator on Wednesday concluded a Johnson & Johnson (J&J) COVID-19 booster dose may be considered for people aged 18 and older at least two months after their initial shot. In a Dec. 15 statement, the European Medicines Agency (EMA) said the recommendation by the agency’s human medicines committee follows data it reviewed showing a second dose of the one-dose vaccine led to a rise in antibodies against the CCP (Chinese Communist Party) virus, which causes the disease COVID-19. The agency noted that the risk of a previously reported side effect, namely a type of clot called cerebral venous sinus thrombosis in combination with low levels of blood platelets, is not known after a booster is administered, adding that it is “being carefully monitored.” “As for all medicines, EMA will continue to look at all data on the safety and effectiveness of COVID-19 Vaccine Janssen,” the agency said in …